EA029707B1 - Гетероциклические ингибиторы глютаминазы - Google Patents

Гетероциклические ингибиторы глютаминазы Download PDF

Info

Publication number
EA029707B1
EA029707B1 EA201590941A EA201590941A EA029707B1 EA 029707 B1 EA029707 B1 EA 029707B1 EA 201590941 A EA201590941 A EA 201590941A EA 201590941 A EA201590941 A EA 201590941A EA 029707 B1 EA029707 B1 EA 029707B1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
aryl
heteroaryl
alkoxy
substituted
Prior art date
Application number
EA201590941A
Other languages
English (en)
Russian (ru)
Other versions
EA201590941A1 (ru
Inventor
Джим Ли
Лицзин Чэнь
Бинду Гоял
Гай Лайдиг
Тимоти Френд Стэнтон
Эрик Брайан Сьегрен
Original Assignee
Калитера Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Калитера Байосайенсиз, Инк. filed Critical Калитера Байосайенсиз, Инк.
Publication of EA201590941A1 publication Critical patent/EA201590941A1/ru
Publication of EA029707B1 publication Critical patent/EA029707B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201590941A 2012-11-16 2013-11-15 Гетероциклические ингибиторы глютаминазы EA029707B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727195P 2012-11-16 2012-11-16
US201361824434P 2013-05-17 2013-05-17
PCT/US2013/070277 WO2014078645A1 (en) 2012-11-16 2013-11-15 Heterocyclic glutaminase inhibitors

Publications (2)

Publication Number Publication Date
EA201590941A1 EA201590941A1 (ru) 2016-02-29
EA029707B1 true EA029707B1 (ru) 2018-05-31

Family

ID=50731715

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590941A EA029707B1 (ru) 2012-11-16 2013-11-15 Гетероциклические ингибиторы глютаминазы

Country Status (25)

Country Link
US (2) US10793535B2 (enExample)
EP (2) EP3954686A1 (enExample)
JP (1) JP6275153B2 (enExample)
KR (1) KR102220175B1 (enExample)
CN (1) CN105051041B (enExample)
AU (1) AU2013344560B2 (enExample)
BR (1) BR112015010955A2 (enExample)
CA (1) CA2891667A1 (enExample)
CY (1) CY1125279T1 (enExample)
DK (1) DK2920168T3 (enExample)
EA (1) EA029707B1 (enExample)
ES (1) ES2899461T3 (enExample)
HR (1) HRP20211610T1 (enExample)
HU (1) HUE056078T2 (enExample)
IL (1) IL238787A0 (enExample)
LT (1) LT2920168T (enExample)
MX (1) MX381260B (enExample)
PL (1) PL2920168T3 (enExample)
PT (1) PT2920168T (enExample)
RS (1) RS62447B1 (enExample)
SG (1) SG11201503720SA (enExample)
SI (1) SI2920168T1 (enExample)
SM (1) SMT202100589T1 (enExample)
WO (1) WO2014078645A1 (enExample)
ZA (2) ZA201504294B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
HUE056078T2 (hu) 2012-11-16 2022-01-28 Calithera Biosciences Inc Heterociklusos glutamináz inhibitorok
HK1220640A1 (zh) * 2012-12-03 2017-05-12 Calithera Biosciences, Inc. 用谷氨醯胺酶的杂环抑制剂治疗癌症
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
HRP20192056T1 (hr) * 2014-04-30 2020-02-21 Pfizer Inc. Derivati diheterocikla vezani na cikloalkil
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
SG11201610333VA (en) 2014-06-13 2017-01-27 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
DK3164195T3 (da) * 2014-07-03 2022-07-11 Univ Texas Glutaminaseinhibitorterapi
WO2016004413A2 (en) * 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
PL3164394T3 (pl) 2014-07-03 2020-09-07 Board Of Regents, The University Of Texas System Inhibitory GLS1 do leczenia chorób
WO2016007647A1 (en) * 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
JP6889101B2 (ja) 2014-08-07 2021-06-18 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤の結晶形態
JP6768693B2 (ja) * 2015-03-30 2020-10-14 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を投与する方法
BR112017021312A2 (pt) * 2015-04-06 2018-06-26 Calithera Biosciences Inc tratamento de câncer de pulmão com inibidores de glutaminase
CN107921044B (zh) 2015-06-30 2022-01-21 德州大学系统董事会 用于治疗疾病的gls1抑制剂
SG11201802830QA (en) 2015-10-05 2018-05-30 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors and immuno-oncology agents
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
KR102777513B1 (ko) 2015-12-22 2025-03-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 (ｒ)-1-(4-(6-(2-(4-(3,3-디플루오로시클로부톡시)-6-메틸피리딘-2-일)아세트아미도)피리다진-3-일)-2-플루오로부틸)-ｎ-메틸-1ｈ-1,2,3-트리아졸-4-카르복사미드의 염 형태 및 다형체
US20180055825A1 (en) * 2016-08-25 2018-03-01 Yu Liang Treatment of cancer with inhibitors of glutaminase
WO2018039544A1 (en) * 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2018039441A1 (en) * 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN110741003B (zh) * 2017-06-13 2021-07-23 南京明德新药研发有限公司 作为gls1抑制剂的化合物
US10722487B2 (en) 2017-10-18 2020-07-28 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN114805346A (zh) * 2021-07-08 2022-07-29 成都硕德药业有限公司 杂环类衍生物、其制备方法及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115698A1 (en) * 2000-08-10 2002-08-22 Newcomb Robert W. Selective inhibition of glutaminase by bis-thiadiazoles
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
WO2013078123A1 (en) * 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
WO1999009825A1 (en) 1997-08-29 1999-03-04 Elan Pharmaceuticals, Inc. Method of preventing neuronal death
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2005113798A2 (en) 2004-04-15 2005-12-01 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US20110281234A1 (en) 2010-05-12 2011-11-17 Colton Crane System and methods for removing a loose tooth
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
HUE056078T2 (hu) 2012-11-16 2022-01-28 Calithera Biosciences Inc Heterociklusos glutamináz inhibitorok
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
HK1220640A1 (zh) 2012-12-03 2017-05-12 Calithera Biosciences, Inc. 用谷氨醯胺酶的杂环抑制剂治疗癌症
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
SG11201610333VA (en) 2014-06-13 2017-01-27 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
JP6889101B2 (ja) 2014-08-07 2021-06-18 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤の結晶形態
JP6768693B2 (ja) 2015-03-30 2020-10-14 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を投与する方法
BR112017021312A2 (pt) 2015-04-06 2018-06-26 Calithera Biosciences Inc tratamento de câncer de pulmão com inibidores de glutaminase
SG11201802830QA (en) 2015-10-05 2018-05-30 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors and immuno-oncology agents
WO2018039544A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
AU2018231058A1 (en) 2017-03-10 2019-09-19 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115698A1 (en) * 2000-08-10 2002-08-22 Newcomb Robert W. Selective inhibition of glutaminase by bis-thiadiazoles
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
WO2013078123A1 (en) * 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAS RN 1400068-83-8, STN Entry Date 08 October 2012 N,N'-(5,5'-(pentane-1,5-diyl)bis(1,3,4-thiadiazole-5,2-diyl))bis(2-methoxybenzamide) *
CAS RN 331234-76-5, STN Entry Date 13 April 2001 N,N'-[thiobis(2,1-etnanediyl-1,3,4-thiadiazole-5,2-diyl)]bis-1H-1,2,4-triazole-3-carboxamide *
Gehlen H., et al. "Uber die Einwirkung von Isocyanaten auf substituierte 2-Amino-1.3.4-oxdiazole", Justus Liebigs Annalen der Chemie, 1966, 692, 151-65 See the first compound of table 2c on page 157 *
Shimano Y., et al. "Syntheses of Poly(diacylthiosemicarbazide)s from Diacylisothiocyanates and Dihydrazides, and Their Thermal Cyclodehydration", Kobunshi Ronbunshu, 1980, 37(2), 131-7 See compound V on page 131 *
Shukla K., et al. "Design, Synthesis and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-l,2,4-thiadiazol-2-yl)ethyl sulphide 3 (BPTES) Analogs as Glutaminase Inhibitors", Journal of Medicinal Chemistry, 2012, 55(23), 10551-10563 See compounds 3, 6, 11a, 11b, 15a, 15b, 15d to 15f, 20 and 27 in table 1 on page 10554, table 1, page 10562 *
Thangavelu K., et al. "Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism", Proceedings of the National Academy of Sciences of the United States of America, 2012,109(20), 7705-7710, S7705/1-S7705/13 See compound 5 on page 6 of 12 of the Supporting Information *

Also Published As

Publication number Publication date
SG11201503720SA (en) 2015-06-29
CN105051041B (zh) 2018-03-30
HRP20211610T1 (hr) 2022-02-04
EA201590941A1 (ru) 2016-02-29
WO2014078645A1 (en) 2014-05-22
HUE056078T2 (hu) 2022-01-28
MX381260B (es) 2025-03-12
PL2920168T3 (pl) 2022-01-03
BR112015010955A2 (pt) 2017-07-11
MX2015005963A (es) 2015-09-16
SI2920168T1 (sl) 2022-01-31
ZA201606590B (en) 2019-04-24
US20140194421A1 (en) 2014-07-10
LT2920168T (lt) 2021-10-25
US20210292289A1 (en) 2021-09-23
CN105051041A (zh) 2015-11-11
US10793535B2 (en) 2020-10-06
CY1125279T1 (el) 2023-03-24
CA2891667A1 (en) 2014-05-22
JP6275153B2 (ja) 2018-02-07
DK2920168T3 (da) 2021-10-18
PT2920168T (pt) 2021-10-18
AU2013344560B2 (en) 2017-09-14
SMT202100589T1 (it) 2021-11-12
HK1215023A1 (zh) 2016-08-12
EP2920168A1 (en) 2015-09-23
IL238787A0 (en) 2015-06-30
EP3954686A1 (en) 2022-02-16
KR102220175B1 (ko) 2021-02-24
EP2920168B1 (en) 2021-07-21
EP2920168A4 (en) 2016-04-20
ZA201504294B (en) 2018-12-19
KR20150085053A (ko) 2015-07-22
RS62447B1 (sr) 2021-11-30
JP2016505526A (ja) 2016-02-25
ES2899461T3 (es) 2022-03-11

Similar Documents

Publication Publication Date Title
ES2899461T3 (es) Inhibidores heterocíclicos de glutaminasa
KR102042290B1 (ko) 글루타미나제의 헤테로사이클릭 억제제
AU2013344560A1 (en) Heterocyclic glutaminase inhibitors
US11471503B2 (en) Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain
EP3610874A1 (en) Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof
EP3313410A1 (en) Compositions and methods for inhibiting arginase activity
EA036001B1 (ru) Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
CA3034890A1 (en) Combination therapy with glutaminase inhibitors
JP2023175716A (ja) リン酸塩誘導体およびその用途
WO2016196890A1 (en) Inhibitors of hexokinase and methods of use thereof
JP2026067904A (ja) Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
US6380206B1 (en) Method of inhibiting neoplastic cells with 4,5-diaminopyrimidine derivatives
AU2016226036B2 (en) Salicylate inhibitors of MELK and methods of use
CA3021677A1 (en) Use of thyroid beta-agonists
HK1215023B (zh) 杂环谷氨酰胺酶抑制剂
HK40010184A (zh) 用谷氨酰胺酶抑制剂的组合疗法

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM